Measuring beta cells: A step toward better type 1 diabetes care?

Type 1 diabetes remains a puzzle with a missing piece: how to stop—or reverse—the immune system’s relentless attack on insulin-producing beta cells. These cells, clustered in the pancreas, are the body’s natural glucose regulators. When they vanish, so does stable blood sugar control. The disease’s trajectory hinges on their survival, making beta cell preservation a central treatment goal, as confirmed by decades of research.

Yet measuring these cells in living patients has been nearly impossible—until now. A emerging body of work, including preclinical studies published in Diabetes, suggests quantitative imaging techniques could finally offer a window into beta cell mass. The premise is straightforward: if clinicians can see how many functional beta cells remain, they might tailor treatments more precisely—slowing destruction or even restoring lost cells.

But this is where the clarity ends and the caveats begin. The studies so far are early-stage, relying on animal models or small human cohorts with limited validation. The imaging methods—often involving radioactive tracers or advanced MRI—are still experimental, with unresolved questions about accuracy, safety, and scalability. As Dr. Emily Burns of Diabetes UK noted in a 2022 review, ‘We’re not yet at the point where this changes clinical practice.’

The clinical relevance today? Essentially none. Patients with type 1 diabetes won’t see beta cell imaging in their next endocrinology visit, nor will it alter their insulin regimens. The real significance lies in what this could enable down the line: personalized therapies. Imagine a scenario where imaging reveals a patient still has 30% of their beta cells intact. A drug like teplizumab, which slows immune destruction, might be prioritized for them over someone with near-total cell loss. Or stem cell transplants—currently a high-risk, last-resort option—could be deployed earlier if imaging shows irreversible decline.

Yet the gaps are glaring. The timeline of beta cell destruction varies wildly between patients, and no imaging tool yet distinguishes functional beta cells from dormant or damaged ones. ‘We’re measuring mass, not necessarily activity,’ cautions Dr. Peter Butler of UCLA’s Larry L. Hillblom Islet Research Center. Then there’s the regulatory hurdle: even if the tech works, it would need FDA or EMA approval as a diagnostic tool—a process that typically takes years.

Most critically, this research doesn’t address the root cause: autoimmunity. Imaging beta cells won’t stop the immune system from attacking them. It’s a diagnostic advance, not a therapeutic one. For now, the focus remains on existing immunotherapies and artificial pancreas systems, which manage symptoms but don’t restore lost cells.

The question isn’t whether this science is promising—it is—but whether it will cross the chasm from lab to clinic. History is littered with ‘almost there’ diabetes breakthroughs that faltered in translation. This time, the stakes are higher: if beta cell imaging delivers, it could redefine how we classify, monitor, and treat type 1 diabetes itself.